

# INVASIVE ASPERGILLOSIS

The reliable result,  
just when you need it

## ASPERGILLUS GALACTOMANNAN Ag VIRCLIA<sup>®</sup> MONOTEST

Sandwich Chemiluminescent Immunoassay (CLIA) for the detection of *Aspergillus* galactomannan antigen in serum, plasma and human bronchoalveolar lavage (BAL) samples.

- Unique and definitive solution for **urgent samples**.
- **Same day results**, no batching, no sample cumulation.
- On-demand testing: **One monotest = one reportable result**. Nothing else is required.
- **Individual Quality Control per monotest**, no need for extra controls or calibrations.
- Simple and **fully automated protocol** with results in about 1h\*.
- **Objective method** with reported results in index values.
- Compatible test with the **broadest panel of infectious diseases in CLIA monotest format (>90 parametres)**.

\* Sample pre-treatment needed. Total assay time 1 hour and 15 minutes approximately.



VirClia<sup>®</sup> MONOTEST - 24 tests

VirClia<sup>®</sup> Lotus

# Invasive Aspergillosis

## The reliable result, just when you need it

### THE TRUE MONOTEST

Vircell has launched a new test for the detection of invasive aspergillosis as an aid for the early diagnosis of this life-threatening disease.

A prompt and accurate diagnosis is essential to establish a proper anti-fungal treatment, as a delay of just 12-24 hours may affect the critical patient survival significantly. Accurate Galactomannan detection also allows to decrease or cancel a prophylactic anti-fungal treatment.

ASPERGILLUS GALACTOMANNAN Ag VIRCLIA® MONOTEST is compatible with the entire VIRCLIA® panel.



**INNOVATIVE TECHNOLOGY**



**MONOTEST FORMAT**



**AUTOMATED RESULTS IN 1 HOUR**



**OPTIMISED ANTIFUNGAL TREATMENT**



**BETTER PATIENT CARE**

### COMPARATIVE PERFORMANCE

ASPERGILLUS GALACTOMANNAN Ag VIRCLIA® MONOTEST is already part of the work routine in laboratories worldwide.

Its excellent performance has been evaluated in a recent publication<sup>1</sup> versus a commercial ELISA as a reference, providing high sensitivity and specificity. VIRCLIA® showed excellent results when analyzing clinical samples compatible with invasive aspergillosis according EORTC/MSGERC\* criteria.

<sup>1</sup> Leyva Calero A, *et al.* (2022) Comparison of the Performance of Two Galactomannan Detection Tests: Platelia Aspergillus Ag and Aspergillus Galactomannan Ag Virclia Monotest. Microbiology Spectrum. American Society of Microbiology. ASM Journals. Microbiology Spectrum. Research article. DOI: <https://doi.org/10.1128/spectrum.02626-2>

#### > Performance vs. commercial ELISA

	Sensitivity	Specificity	No. of samples
<b>VIRCLIA®</b>	93.8%	89.5%	n= 327

#### > Performance according clinical EORTC/MSGERC\* criteria

	Sensitivity	Specificity	No. of samples
<b>VIRCLIA®</b>	80.9%	100%	n= 120
<b>ELISA</b>	63.2%	100%	

\* EORTC/MSGERC: European Organisation for Research and Treatment of Cancer and Mycoses Study Group Education and Research Consortium definitions of invasive fungal diseases

### INFORMATION AND RELATED PRODUCTS

Description	Cat. No.	Content / Capacity
ASPERGILLUS GALACTOMANNAN Ag VIRCLIA® MONOTEST <b>NEW</b>	<b>VCM073</b>	24 tests
INVASIVE CANDIDIASIS (CAGTA) VIRCLIA® IgG MONOTEST	<b>VMC094</b>	24 tests
VIRCLIA® LOTUS	<b>VCLTS-CL</b>	40 monotests

Vircell S.L.  
Parque Tecnológico de la Salud, Avicena 8, 18016 Granada, Spain  
info@vircell.com [www.vircell.com](http://www.vircell.com)

Not for general supply unless first included in the Australian Register of Therapeutic Goods.



Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | [info@abacusdx.com](mailto:info@abacusdx.com) | [www.abacusdx.com](http://www.abacusdx.com)



PME096-04/22